Maplelane Capital’s AbbVie ABBV Stock Holding History

Maplelane Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-260,000	Closed	-$21M	–	114
2019 Q1	$21M	Sell	260,000 -260,000	-50%	-$21.3M	0.59%	51
2018 Q4	$47.9M	Buy	520,000 +70,000	+16%	+$6.16M	1.39%	21
2018 Q3	$42.6M	Buy	450,000 +250,000	+125%	+$23.7M	1.41%	22
2018 Q2	$18.5M	Buy	+200,000	New	+$19.5M	0.4%	67

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Maplelane Capital's ABBV Position: Q1 2019 in Review

Maplelane Capital sold out of AbbVie (ABBV) in Q1 2019, closing a stake of 1 share — an estimated $82 sold.

Maplelane Capital first reported a position in ABBV in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 2,033 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

Maplelane Capital reported no remaining AbbVie position as of Q1 2019 after selling out during the quarter.
Maplelane Capital sold 1 AbbVie share in Q1 2019, an estimated $82.
Maplelane Capital first reported a position in AbbVie in Q4 2018 and held it in 1 quarter.
Maplelane Capital's AbbVie position peaked at $0 in Q4 2018.
2,033 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on Maplelane Capital's 13F filing for Q1 2019, filed 15 May 2019.